BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33100329)

  • 1. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
    Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
    Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
    Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
    DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
    Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
    Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-Associated Fibroblast-Derived IL-8 Upregulates PD-L1 Expression in Gastric Cancer Through the NF-κB Pathway.
    Lou M; Iwatsuki M; Wu X; Zhang W; Matsumoto C; Baba H
    Ann Surg Oncol; 2024 May; 31(5):2983-2995. PubMed ID: 38006530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
    Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K
    Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
    Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
    Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 19. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.
    Shi Y; Fan X; Meng W; Deng H; Zhang N; An Z
    Breast Cancer Res; 2014 Apr; 16(2):R33. PubMed ID: 24693969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y
    BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.